Navigation Links
Tel Aviv University to spearhead groundbreaking nanotechnology consortium
Date:10/25/2012

Tel Aviv University has been appointed by the Israel National Nanotechnology Initiative (INNI) to lead a consortium on "Nanomedicines for Personalized Theranostics," a combined system of diagnostics and therapeutic treatments. This consortium of 11 laboratories will be dedicated to developing nano-sized drug delivery systems for the detection and treatment of various diseases. Eight of the labs are TAU-led, with additional participation from Hebrew University Jerusalem, Bar-Ilan University and Ben Gurion University of the Negev.

The $11.5 million project, designated a Focal Theology Area (FTA) within the INNI and scheduled to last five years, is poised to create a center of excellence in nanotechnology in Israel, says Scientific Director Prof. Dan Peer of TAU's Department of Cell Research and Immunology and Center for Nano Science and Nano Technology. The FTA will be supported by an international scientific advisory board, headed by internationally renowned Prof. Robert Langer of MIT.

The ultimate goal is to design a new class of drugs that can destroy faulty proteins in angiogenesis-dependent diseases that involve the growth of new blood vessels from existing vessels including cancer, infectious diseases and heart diseases and deliver these drugs safely into the body. Beyond the academic realm, the group aims to create spin-off companies based on licensed technologies they develop, creating the basis for a thriving biotechnology industry within Israel.

Building a successful industry

Although considered a beacon of research and development, the field of biotechnology in Israel has suffered drawbacks, both in academia and industry. Higher salaries lure the best minds abroad, and international companies have more private capital with which to sustain businesses.

"Israel has amazing intellectual resources, but we are constantly combating budget constraints. With this project, the idea is to create future technologies built on Israeli creativity that also allow us to bring in the brightest people and better funding," says Prof. Peer. While many great biotechnology ideas were born in Israel, the economic situation stymied the establishment of many more successful companies within the country, he observes. "We want to maintain the advantages that we have in the life sciences while boosting this lagging industry. Our research as part of the FTA will be a starting engine."

Prof. Peer hopes that in two years, researchers will be able to start translating their research into practical applications.

The INNI is also working to combat "brain drain" in the academic world by giving TAU and other institutions the means to attract outstanding young researchers back home to Israel, both with funding and with the prestige of the project. New faculty positions at TAU are already being filled, and will continue to be created as part of FTA.

A personalized theranostics approach

This research project is poised to answer a crucial need in modern medicine, advancing the fields of theranostics and personalized medicine.

The major goal of the project is to design a new class of drugs based on genomic information taken from each patient, and then use nano carriers to deliver appropriate drug therapy into specific cell types. Because each patient is biologically different, a one-size-fits-all medical solution doesn't always give the best therapeutic results. "Each person reacts differently to medications," explains Prof. Peer. "In the long term, the idea is to tailor-make not only the drug carrier, but the drug itself for a personalized approach."


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Related biology technology :

1. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
2. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
3. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
4. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
5. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
6. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
7. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
8. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
9. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
10. Worlds smallest semiconductor laser created by University of Texas scientists
11. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 02, 2016 , ... In anticipation of AxioMed’s exclusive cleanroom ... company President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. ... Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received ...
(Date:12/2/2016)... ANGELES , Dec. 2, 2016 CytRx ... and development company specializing in oncology, today announced the ... noted sarcoma surgeon, industry consultant, and private healthcare investor, ... is a healthcare leader with clinical and strategic experience ... , CytRx,s Chairman and CEO. "As one of the ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... for North American hospitals, will present its chain-of-custody solution for tracking and securing ... Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... Nanowear on their recent FDA Class II 510(k) clearance for their flagship medical ... in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/24/2016)... Calif. , Nov. 23, 2016 Cercacor ... endurance athletes and their trainers non-invasively measure ... Index, Pulse Rate, and Respiration Rate in approximately 30 ... enables users easy and immediate access to key data ... part of a training regimen. Hemoglobin ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
Breaking Biology News(10 mins):